Sunday (Daytime Members/Donors Only 10:00 am to Noon): 12:00 pm—5:00 pm ...

Sunday (Daytime Members/Donors Only 10:00 am to Noon): 12:00 pm—5:00 pm ...

BOSTON, June 8, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage oncology company advancing a three-platform pipeline in RNA therapeutics and immuno-oncology, today ...

BOSTON, June 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today ...

BOSTON, May 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today ...

We have updated our Privacy Policy. Please review to learn more. By continuing to use our services, you agree to these updates. By Patty Nieberg Published Apr 22 ...

WASHINGTON — The U.S. Army today announced the implementation of the new Combat Field Test (CFT), a major update to its physical readiness program designed to align fitness standards with the ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Ellen Lee Ellen Lee is a writer focused on parenting and health gear. She has ...

TransCode Therapeutics named Philippe Calais, Ph.D., as its CEO in a statement to disclose a pair of deals. (Feodora Chiosea/Getty Images) In a pair of deals, TransCode Therapeutics has bagged ...

What happens when a trusted tech brand makes a decision that fundamentally alters how its products are used? For Synology, the answer is unfolding in real-time, as its recent move to eliminate ...

HWA Tester (hwatest) is a Python 3 CPU and Hardware Acceleration (GPU) tester for Jellyfin. This program runs a series of standardized tests to determine how video transcoding will perform on your ...

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced further progress on Thursday in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer. To date, 13 patients have received at ...